Clinical and laboratory profiles of Oropouche virus disease from the 2024 outbreak in Manaus, Brazilian Amazon
PLOS Neglected Tropical Diseases · 2025
DOI: 10.1371/journal.pntd.0013604 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Maria Paula Gomes Mourão und 28 weiteren Autor:innen. Beteiligte Einrichtung: Diretoria de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil. Hauptthemen laut MEDLINE: Bunyaviridae Infections, Disease Outbreaks, Orthobunyavirus. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Instituto Todos pela Saude, Fundação de Amparo à Pesquisa do Estado do Amazonas.
Abstract (Originalsprache)
Background
The 2024 Oropouche virus (OROV) outbreak in Brazil raised public health concerns due to its unprecedented rapid spread, high incidence, and potential neurological complications. OROV symptoms overlap with locally endemic arbovirus diseases, like dengue virus (DENV), complicating diagnosis. The study aimed to compare clinical, laboratory, and immunological profiles in OROV and DENV cases, crucial for improving diagnosis and management.
Methods
This study analyzed 51 OROV and 78 of DENV cases consecutively enrolled in Manaus, Amazonas, Brazil, and monitored for 28 days. OROV diagnosis was performed by real-time PCR (RT-PCR) using serum and urine samples. OROV RT-PCR positive samples were genotyped. A paired Plaque Reduction Neutralization Test (PRNT) was conducted on samples collected at D1 and D28. Patients with a ≥ 4-fold increase in neutralizing antibody titer between D1 and D28 were considered OROV-positive. Clinical manifestations, hematology, biochemistry, and cytokine profiles were analyzed. Statistical analysis included comparison between OROV and DENV patients.
Results
Genome sequencing of OROV isolates confirmed presence of a previously reported novel reassortment event, consistent with ongoing localized transmission. Urine RT-PCR demonstrated low positivity compared to serum samples. The paired PRNT increased sensitivity in 45%. Clinically, OROV infection was associated with significantly higher frequencies of severe headache, myalgia, arthralgia, and rash compared to DENV infection (p < 0.001). Elevated alanine aminotransferase (ALT) levels were also observed in OROV patients (p < 0.001). Immunologically, OROV infection induced significantly increased levels of acute-phase CCL11 (eotaxin), CXCL10, IFN-γ, IL-1RA, and IL-10, which declined by day 28, while IL-5 increased during recovery. In contrast, DENV patients exhibited elevated levels of CCL2, G-CSF, and CCL3 in recovery phase.
Conclusion
OROV symptoms overlap with DENV underscores the need for syndromic diagnostic approach in endemic regions. Continued genomic surveillance and expanded clinical studies are vital to assess long-term consequences. Given OROV’s expanding geographic range, targeted public health measures are essential to mitigate future outbreaks and better understand its pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diretoria de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
- Escola Superior de Ciências da Saúde, Universidade do Estado do Amazonas, Manaus, Brazil.
- Laboratório de Pesquisas em Virologia, Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil.
- Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
- Escola de Saúde Pública de Manaus, Secretaria Municipal de Saúde, Manaus, Brazil.
- Programa de Residência Médica em Cirurgia, Hospital Adventista de Manaus, Manaus, Brazil.
ORCID-Profile: Marco Aurélio Sartim, Wuelton Monteiro
Förderung
- NIAID NIH HHS
- Instituto Todos pela Saude
- Fundação de Amparo à Pesquisa do Estado do Amazonas
- Conselho Nacional de Desenvolvimento CientÃfico e Tecnológico
- Fiocruz/FIOTEC
- National Institute of Health
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Gomes Mourão, M. P., de Melo, G. C., Nascimento, J., Mwangi, V. I., Sacchetto, L., Gardinassi, L. G., Linhares Abreu Netto, R., Mota, J., Pinto, S. D., Tavares, M., Cordeiro, L. M., de Castro, B. S., Brasil, A., Porto, D. D. S., Silva de Oliveira, B. D., Shuan Laco, A. C., de Souza, L. P., Bentes, K. O., Castilho, M., …, & Monteiro, W. (2025). Clinical and laboratory profiles of Oropouche virus disease from the 2024 outbreak in Manaus, Brazilian Amazon. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013604
Vancouver
Gomes Mourão MP, de Melo GC, Nascimento J, Mwangi VI, Sacchetto L, Gardinassi LG, et al. Clinical and laboratory profiles of Oropouche virus disease from the 2024 outbreak in Manaus, Brazilian Amazon. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013604
BibTeX
@article{GomesMouro2025,
author = {Gomes Mourão, Maria Paula and de Melo, Gisely Cardoso and Nascimento, Joabi and Mwangi, Victor Irungu and Sacchetto, Livia and Gardinassi, Luiz Gustavo and Linhares Abreu Netto, Rebeca and Mota, Jady and Pinto, Sergio Damasceno and Tavares, Mayara and Cordeiro, Liz Moreira and de Castro, Barbara Seffair and Brasil, de Abreu and Porto, Dyandra Dos Santos and Silva de Oliveira, Bianca Daniele and Shuan Laco, Ana Carolina and de Souza, Lorenna Pereira and Bentes, Karolaine Oliveira and Castilho, Marcia and Morais, Carlos Eduardo and Lira, Heline Silva and Alho, Luís Felipe and Martínez Espinosa, Flor Ernestina and Sampaio, Vanderson and Murta, Felipe and Sartim, Marco Aurélio and Nogueira, Maurício Lacerda and Lacerda, Marcus and Monteiro, Wuelton},
title = {Clinical and laboratory profiles of Oropouche virus disease from the 2024 outbreak in Manaus, Brazilian Amazon},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
doi = {10.1371/journal.pntd.0013604}
}
EUVIMED